Reference : Serotonin, personality and borderline personality disorder
Scientific journals : Article
Social & behavioral sciences, psychology : Neurosciences & behavior
Human health sciences : Psychiatry
Serotonin, personality and borderline personality disorder
Hansenne, Michel mailto [Université de Liège - ULiège > Département des sciences cognitives > Psycho. de la personnalité et des différences individuelles >]
Pitchot, William mailto [Centre Hospitalier Universitaire de Liège - CHU > > Psychiatrie et psychologie médicale >]
Ansseau, Marc mailto [Centre Hospitalier Universitaire de Liège - CHU > > Psychiatrie et psychologie médicale >]
Acta Neuropsychiatrica
Blackwell Munksgaard
Yes (verified by ORBi)
[en] personality ; borderline personality disorder ; serotonin
[en] Serotonin is one of the neurotransmitters implicated in normal personality Many psychobiological models of personality include,some dimensions related to serotonin. For instance, the harm avoidance dimension of the blosocial model developed by Cloninger is related to serotonergic activity Higher scores on the harm avoidance dimension should theoretically reflect increased serotonergic activity However, correlation studies related serotonin activity to harm avoidance dimension have not yielded consistent findings. These controversial results are probably related to the complexity of the neurotransmitter systems, and the different assessment techniques used in these studies. Finally, recent genetic studies have examined the association between personality dimensions and serotonergic receptor polymorphisms with mixed results. Serotonin is not only related to some dimensions of normal personality Several psychopathological disorders are associated with serotonergic dysfunction. More particularly, borderline personality disorder (BPD) can be defined by many of the symptoms associated with serotonergic dysregulation, including affective lability, suicidal behaviours, impulsivity and loss of impulse control. Indeed, several reports have demonstrated the efficacy of selective serotonin re-uptake drugs in treating the depressive and impulsive symptoms of patients with BPD. Moreover, some challenge studies have reported a lower serotonergic activity in BPD. Because these challenges are not specific, we have assessed the serotonergic activity in BPD with the flesinoxan challenge. Preliminary results showed that the prolactine responses to flesinoxan were significantly lower in BPD patients compared to those observed in controls.

File(s) associated to this reference

Fulltext file(s):

Open access
Hansenne Acta Neuropsychiatrica 2002.pdfAuthor postprint115.21 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.